1. A method of reducing the level of myo-inositol in the brain of a subject, comprising administering to said subject an effective amount of scylo-inositol. A method for reducing the levels of myo-inositol in the brain of a patient suffering from dementia, mild Alzheimer's disease, mild cognitive impairment, or bipolar disorder, the method comprising: administering to the patient a therapeutically effective amount of scylo-inositol during a therapeutically effective treatment period, the administration of scylo-inositol reduces levels myo-inositol in the patient’s brain compared to the baseline measured before administration. 3. The method according to claim 1, characterized in that the effective amount of scylo-inositol is from about 125 mg to about 900 mg per day. The method according to claim 3, characterized in that scillo-inositol is administered twice a day. The method according to claim 1, characterized in that the introduction reduces the level of myo-inositol in the brain of the patient by a value of from about 20% to about 50% compared with the initial level measured before administration. A method for delaying the occurrence of at least two new neuropsychiatric symptoms in a patient, the method comprising: administering to a specified patient a therapeutically effective amount of scylo-inositol during a therapeutically effective treatment period, the administration of scylo-inositol delays the occurrence of at least two new neuropsychiatric symptoms during the treatment period relative to the initial state determined prior to administration. 7. The method according to claim 6, characterized in that the patient suffers from Alzheimer's dementia, frontotemporal dementia, vascular deme1. Способ снижения уровня мио-инозитола в мозге субъекта, включающий введение указанному субъекту эффективного количества сцилло-инозитола.2. Способ снижения уровней мио-инозитола в мозге пациента, страдающего деменцией, болезнью Альцгеймера легкой степени, умеренным когнитивны
